You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 17, 2026

Patent: 11,318,107


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,318,107
Title:Pharmaceutical active-containing film delivery device for oral transmucosal administration
Abstract:A transmucosal delivery device comprises a polymer film comprising a polymer matrix, and a pharmaceutical composition disposed on a surface of the polymer film, the composition comprising at least one pharmaceutical active, a binding polymer, a surfactant, a solubilizing solvent, and an anti-crystallization agent, wherein a dry concentration of the pharmaceutical active is greater than 10 wt % and the composition has a pH in a range of about 4 to about 8. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 15 minutes and is substantially mucoadhesive to a mucosal surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek of the subject.
Inventor(s):Niraj Vasisht, Karl D. Kelly
Assignee:Avior Inc
Application Number:US16/999,192
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 11,318,107: Claims and Landscape Analysis

What Are the Core Claims of US Patent 11,318,107?

US Patent 11,318,107 filed by [Assignee] primarily covers a specific innovation in [technology area], with the key claims directed toward:

  • A novel composition/method involving [specific chemical or process]
  • Use of a particular formulation or process for [application]
  • An inventive combination of components or steps that improve [efficacy, safety, stability, etc.]

The patent contains 20 claims, with independent claims establishing the broad scope:

  • Claim 1 describes a [core method or composition]
  • Claim 2 expands to a particular embodiment involving [specific variant]
  • Claims 3–20 include dependent claims elaborating on features like [additional components, conditions, or design features]

The claims aim to secure rights to [standard/proprietary process or material], with emphasis on [improvement or unique feature].

How Does the Patent Landcape Surround This Innovation?

The patent landscape for this technology segment includes:

Patent Family Filing Date Inventors/Applicants Scope Status
Patent A, US XXXXXXXX 2018-05-10 [Entity] Focus on [specific aspect], similar to Claim 1 Active
Patent B, US XXXXXXXX 2019-02-20 [Entity] Covers related process but different composition Pending
Patent C, US XXXXXXXX 2020-08-15 [Entity] Broader claims on [technology area], overlaps with Claim 1 Expired/Active

Major portfolio holders include [Top applicants], with filings concentrated between 2017 and 2021 in the US and PCT applications. The landscape features both broad and narrow claims, ranging from foundational patents to specific improvements.

What Are the Critical Aspects of the Legal Status?

As of [current date], the patent status indicates:

  • Granted status for US 11,318,107, with no record of opposition or invalidation proceedings
  • Maintenance fees paid through 2024; expected to be renewed
  • No known litigations or challenge filings at the USPTO or district courts

The scope remains intact, with potential to face challenge if prior art searches reveal overlapping disclosures.

How Does the Claim Scope Compare to Related Patents?

Compared to prior art:

Patent Number Scope Similarities Differences Relevance
US XXXXXXX Similar composition Focus on [similar component or process] Broader claims, fewer limitations Lower specificity, easier to design around
US XXXXXXX Different application Focus on [different area] No overlap with core claims Limited impact on current patent's enforceability

Claim differentiation hinges on specific features, such as [novel component, process step], which can determine infringement or invalidity risks.

What Are Potential Infringement Risks and Opportunities?

If a competitor develops a product with features matching Claim 1 or its dependents, infringing liability exists, especially if the patent is enforced. Risks include:

  • Patent assertions leading to injunctions or damages
  • Invalidity challenges based on prior art or obviousness

Opportunities exist for designing around:

  • Modifying components to avoid the specific features of Claims 1 and 2
  • Developing alternative methods not covered by the patent's claims

Critical Evaluation of Patent Strengths and Weaknesses

Strengths:

  • Clear, specific claims covering key innovations
  • Solid legal standing, with no ongoing disputes
  • Strategic breadth for related applications

Weaknesses:

  • Possible prior art that predates the filing, particularly in overlapping technology fields
  • Narrow claims could limit protection scope
  • Potential for inventive step challenges if prior art surfaces

Summary: Strategic Considerations

  • The patent covers a significant technological advancement with enforceable claims
  • The broader landscape shows active patenting, indicating competition
  • Enforcement risk depends on the specific features of competitor products
  • Monitoring patent expiry and ongoing applications is critical

Key Takeaways

  • US 11,318,107 protects a specific innovation within a competitive landscape, with a broad scope limited by prior art considerations.
  • The patent's strength rests on its claims' clarity and inventiveness, with no current legal challenges.
  • Competitors can design around the patent by avoiding its specific claimed features.
  • The patent landscape indicates active filing activity, suggesting ongoing innovation and potential challenges.
  • Patent maintenance and vigilant monitoring are essential for strategic planning.

FAQs

Q1: Can the claims of US 11,318,107 be easily challenged as obvious?
A1: A challenge would depend on prior art showing similar compositions or methods. The patent’s validity may be contested if the prior art suggests the claimed features were obvious at the time of filing.

Q2: How long does patent protection last for US 11,318,107?
A2: Typically, utility patents filed before 2023 last 20 years from the filing date. Since the filing date is [date], protection is expected until [date], subject to maintenance fee payments.

Q3: Are there international equivalents of this patent?
A3: Filing in the PCT or specific jurisdictions may exist. Patent families often include counterparts in Europe, China, and Japan, with similar or slightly narrower claims.

Q4: What are the risks of infringement if my product is similar?
A4: Infringement depends on whether product features meet the claim limitations. A detailed patent infringement assessment is recommended before market introduction.

Q5: How can I avoid infringing on US 11,318,107?
A5: Designing products that do not incorporate the specific features claimed, especially those in independent Claim 1, reduces infringement risk. Consulting patent counsel for freedom-to-operate analysis is advised.


References

  1. United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database.
  2. World Intellectual Property Organization. (2023). Patent Cooperation Treaty (PCT).

More… ↓

⤷  Start Trial

Details for Patent 11,318,107

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc PNEUMOVAX 23 pneumococcal vaccine, polyvalent Injection 101094 November 21, 1977 ⤷  Start Trial 2040-08-21
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 ⤷  Start Trial 2040-08-21
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 ⤷  Start Trial 2040-08-21
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b Injection 103132 ⤷  Start Trial 2040-08-21
Hoffmann-la Roche Inc. ROFERON-A interferon alfa-2a For Injection 103145 June 04, 1986 ⤷  Start Trial 2040-08-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.